1
|
Iacobucci I, Papayannidis C. SOHO State of the Art Updates and Next Questions | Approach to BCR::ABL1-Like Acute Lymphoblastic Leukemia. CLINICAL LYMPHOMA, MYELOMA & LEUKEMIA 2024:S2152-2650(24)00296-9. [PMID: 39217000 DOI: 10.1016/j.clml.2024.08.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/31/2024] [Accepted: 08/06/2024] [Indexed: 09/04/2024]
Abstract
Philadelphia-like (Ph-like) or BCR::ABL1-like acute lymphoblastic leukemia (ALL) is a common high-risk subtype of B-cell precursor ALL (B-ALL) characterized by a diverse range of genetic alterations that challenge diagnose and converge on distinct kinase and cytokine receptor-activated gene expression profiles, resembling those from BCR::ABL1-positive ALL from which its nomenclature. The presence of kinase-activating genetic drivers has prompted the investigation in preclinical models and clinical settings of the efficacy of tyrosine kinase inhibitor (TKI)-based treatments. This was further supported by an inadequate response to conventional chemotherapy, high rates of induction failure and persistent measurable residual disease (MRD) positivity, which translate in lower survival rates compared to other B-ALL subtypes. Therefore, innovative approaches are underway, including the integration of TKIs with frontline regimens and the early introduction of immunotherapy strategies (monoclonal antibodies, T-cell engagers, drug-conjugates, and CAR-T cells). Allogeneic hematopoietic cell transplantation (HSCT) is currently recommended for adult BCR::ABL1-like ALL patients in first complete remission. However, the incorporation of novel therapies, a more accurate diagnosis and a more sensitive MRD assessment may modify the risk stratification and the indication for transplant in these patients.
Collapse
Affiliation(s)
- Ilaria Iacobucci
- Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA.
| | - Cristina Papayannidis
- IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia Seragnoli, Bologna, Italy
| |
Collapse
|
2
|
Wang R, Zhao C, Jiang S, Zhang Z, Ban C, Zheng G, Hou Y, Jin B, Shi Y, Wu X, Zhao Q. Advanced nanoparticles that can target therapy and reverse drug resistance may be the dawn of leukemia treatment: A bibliometrics study. Front Bioeng Biotechnol 2022; 10:1027868. [PMID: 36299285 PMCID: PMC9588980 DOI: 10.3389/fbioe.2022.1027868] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2022] [Accepted: 09/14/2022] [Indexed: 12/24/2022] Open
Abstract
With the development of nanomedicine, more and more nanoparticles are used in the diagnosis and treatment of leukemia. This study aimed to identify author, country, institutional, and journal collaborations and their impacts, assess the knowledge base, identify existing trends, and uncover emerging topics related to leukemia research. 1825 Articles and reviews were obtained from the WoSCC and analyzed by Citespace and Vosviewer. INTERNATIONAL JOURNAL OF NANOMEDICINE is the journal with the highest output. The contribution of FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY is also noteworthy. The three main aspects of research in Nanoparticles-leukemia-related fields included nanoparticles for the diagnosis and treatment of leukemia, related to the type and treatment of leukemia, the specific molecular mechanism, and existing problems of the application of nanoparticles in leukemia. In the future, synthesize nano-drugs that have targeted therapy and chemotherapy resistance according to the mechanism, which may be the dawn of the solution to leukemia. This study offers a comprehensive overview of the Nanoparticles-leukemia-related field using bibliometrics and visual methods for the first time, providing a valuable reference for researchers interested in Nanoparticles-leukemia.
Collapse
Affiliation(s)
- Rui Wang
- Department of Hematology, Shandong Second Provincial General Hospital, Jinan, China
| | - Changming Zhao
- Department of Hematology, Shandong Second Provincial General Hospital, Jinan, China
| | - Shuxia Jiang
- Department of Hematology, The Qinghai Provincial People’s Hospital, Xining, China
| | - Zhaohua Zhang
- Department of Hematology, The Qinghai Provincial People’s Hospital, Xining, China
| | - Chunmei Ban
- Department of Hematology, Hematology Department, The People’s Hospital of Liuzhou City, Liuzhou, China
| | - Guiping Zheng
- Department of Hematology, The Qinghai Provincial People’s Hospital, Xining, China
| | - Yan Hou
- Department of Hematology, The Qinghai Provincial People’s Hospital, Xining, China
| | - Bingjin Jin
- Department of Pharmacy, The Qinghai Provincial People’s Hospital, Xining, China
| | - Yannan Shi
- Department of General Medicine, Ganmei Hospital, Kunming First People’s Hospital, Kunming, China
| | - Xin Wu
- Department of Spine Surgery, Third Xiangya Hospital, Central South University, Changsha, China
- *Correspondence: Xin Wu, ; Qiangqiang Zhao,
| | - Qiangqiang Zhao
- Department of Hematology, The Qinghai Provincial People’s Hospital, Xining, China
- *Correspondence: Xin Wu, ; Qiangqiang Zhao,
| |
Collapse
|
3
|
Peters C, Balduzzi A, Bader P. Editorial: Allogeneic haematopoietic stem cell transplantation for children with acute lymphoblastic leukaemia in the era of immunotherapy. Front Pediatr 2022; 10:959471. [PMID: 36052358 PMCID: PMC9426657 DOI: 10.3389/fped.2022.959471] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/01/2022] [Accepted: 08/02/2022] [Indexed: 11/13/2022] Open
Affiliation(s)
- Christina Peters
- Stem Cell Transplantation Unit, Department of Pediatrics, St. Anna Children's Hospital, Children's Cancer Research Institute, Medical University of Vienna, Vienna, Austria
| | - Adriana Balduzzi
- Clinica Pediatrica Università degli Studi di Milano-Bicocca, Fondazione MBBM, Monza, Italy
| | - Peter Bader
- Division for Stem Cell Transplantation, Immunology and Intensive Care Medicine, Department for Children and Adolescents, University Hospital, Goethe University, Frankfurt, Germany
| |
Collapse
|